The FDA approved UroGen’s Zusduri (mitomycin formulation) for recurrent low-grade, intermediate-risk, non-muscle invasive bladder cancer after a narrowly negative advisory committee vote. Clinical trial data showed a 78% complete response at three months and a favorable 12-month event-free rate. The approval offers a nonsurgical treatment alternative to repeated transurethral resection and aims to reduce surgical burden.